Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Strategy Stock: Bitcoin Bet Defies Market Slump

Robert Sasse by Robert Sasse
August 5, 2025
in Stocks
0
Strategy Stock
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

Despite reporting record Q2 2025 earnings, MicroStrategy’s shares plunged 9% amid broader crypto-market weakness triggered by a disappointing US jobs report. The software firm surpassed profit expectations, raising its Bitcoin KPI targets for the second time this year and projecting $34 billion in operating income. Analysts maintained bullish outlooks, with one institution lifting its price target to $700, citing growing institutional adoption and regulatory clarity.

Aggressive Accumulation Pays Off

MicroStrategy purchased an additional 21,021 Bitcoin for $2.46 billion in early August, bringing its total holdings to 628,791 BTC ($72 billion at current prices). The company funded the spree through a $2.52 billion preferred stock offering and retains access to billions more via ATM programs. Trading at just 1.64x net asset value—20% below historical averages—the stock appears undervalued given its Bitcoin reserves. Meanwhile, a Japanese firm mirrored the strategy, acquiring 463 BTC, signaling widening institutional interest.

Ad

Strategy Stock: Buy or Sell?! New Strategy Analysis from March 25 delivers the answer:

The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Strategy: Buy or sell? Read more here...

Tags: Strategy
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Eli Lilly Stock
Stocks

Eli Lilly’s Strategic Diversification Amid Weight-Loss Drug Competition

November 18, 2025
Micron Stock
Stocks

Micron Shares Approach Peak: What Comes After the AI Rally?

November 18, 2025
Varonis Stock
Stocks

Varonis Shares Plunge Amidst Mixed Signals

November 18, 2025
Next Post
Simon Property Stock

Simon Property Stock: Soars on Record Earnings and Expansion

Fraport Stock

Fraport Stock: Strong Earnings Defy Revenue Dip

Fresenius Medical Care Stock

Fresenius Medical Care Stock: Mixed Q2 Results Amid Challenges

Recommended

Technology Blockchain Trading online

Analyst Reaffirms Bullish Outlook on CyberArk Software with 300 Price Target

2 years ago
Pepsi Stock

PepsiCo’s Leadership Shift Amid Market Headwinds

4 months ago
Nvidia Stock

Nvidia’s AI Dominance Faces Critical Test as Key Client Explores Alternatives

4 months ago
Palantir Stock

Palantir Shares Navigate Market Turbulence

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Regulatory Scrutiny Looms Over Alphabet’s Aggressive AI Expansion

Ocugen Shares Tumble Despite Positive Clinical Trial Results

Regulatory Proposal Sparks Sell-Off in Coinbase Shares

UnitedHealth Faces Multifaceted Regulatory Scrutiny Ahead of Earnings

Intel’s Capital Reshuffle and Leadership Transition Revealed in Annual Filing

35,000 Guards for 359 Million Doors: The Cyber Deficit Wall Street Can No Longer Ignore

Trending

Pinduoduo Stock
Asian Markets

Pinduoduo’s Upcoming Earnings: A Critical Test for the E-Commerce Giant

by SiterGedge
March 25, 2026
0

All eyes are on Pinduoduo this Wednesday as the company prepares to release its fourth-quarter 2025 financial...

XPeng Stock

XPeng Achieves Profitability Milestone Amid Strategic Mexican Launch

March 25, 2026
Oracle Stock

Oracle’s Backlog Soars on Cloud and AI Contract Momentum

March 25, 2026
Alphabet Stock

Regulatory Scrutiny Looms Over Alphabet’s Aggressive AI Expansion

March 25, 2026
Ocugen Stock

Ocugen Shares Tumble Despite Positive Clinical Trial Results

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Pinduoduo’s Upcoming Earnings: A Critical Test for the E-Commerce Giant
  • XPeng Achieves Profitability Milestone Amid Strategic Mexican Launch
  • Oracle’s Backlog Soars on Cloud and AI Contract Momentum

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com